The present invention provides methods and compositions to reduce binding of fibrinogen to the ClfA in a gram positive bacterial infections using monoclonal antibody, a polyclonal antibody, an antigen-binding antibody fragment or a composition that specifically binds to a portion of ClfA with the sequence of SEQ ID No: 15, SEQ ID NO: 16, SEQ ID NO: 17, and SEQ ID NO: 18.

The present invention provides anti-Fzd monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.

This method for producing a protein crystal includes: a step (a) for adding, to a protein synthesis system, a nucleic acid that encodes crystalline protein; and a step (b) for incubating the protein synthesis system during the predetermined time until the crystalline protein encoded by the added nucleic acid is expressed and the expressed crystalline protein completes the formation of crystals, wherein the protein synthesis system is a cell-free protein synthesis system.

The present invention relates to the field of medical biology, and discloses a high-resolution crystal structure of a complex of PD-L1-blocking heavy-chain single-domain antibody KN035 binding with PD-L1, and the use of the crystal structure. The invention also relates to novel PD-L1 binding polypeptides or compounds developed based on the crystal structure and uses thereof.

Presented herein, in certain embodiments, are bi-specific binding agents comprising an antibody portion that binds specifically to syndecan-1 and a Fynomer portion that binds specifically to a Fibroblast Growth Factor Receptor 3 (FGFR3), compositions thereof and uses thereof for treating a neoplasm.

Described herein are antibodies that target Leukemia Inhibitory Factor (LIF). Also described herein are uses of these antibodies for the treatment of cancer.

Disclosed are a method for treating a tumor using a CTLA4-binding protein and a use thereof, wherein the CTLA4-binding protein specifically binds to CTLA4 and does not compete with a ligand of CTLA4 for binding to CTLA4. The CTLA4-binding protein described in the present application can effectively inhibit tumor growth.

The present disclosure provides human antibodies and fragments thereof having binding specificity to the SARS-CoV-2 spike protein's receptor binding domain (RBD). The antibodies and fragments have strong affinity and potent neutralization ability against the SARS-CoV-2 virus and various mutant forms. Also provided are trimeric antibodies which have further enhanced neutralization capabilities. The antibodies and fragments thus may be used for preventing or treating SARS-CoV-2 viral infection or detecting the presence of the virus in a sample.

IL-18 participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.

Herein is reported a bispecific antibody comprising a first binding specificity that specifically binds to a haptenylated payload and a second binding specificity that specifically binds to a blood brain barrier receptor.